Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...

Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone was non-inferior to IV Sarclisa in relapsed/refractory multiple myeloma.

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...

“They often affect both herd profitability and animal welfare,” he said Injection-site lesions are typically made of scar tissue that forms in the muscle or subcutaneous tissue following an injection.

BioArctic announces US FDA accepts Eisai’s BLA for subcutaneous maintenance dosing of Leqembi: Stockholm Wednesday, January 15, 2025, 13:00 Hrs [IST] BioArctic AB (publ) announc ...

( MENAFN - JCN NewsWire) FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the treatment of Early Alzheimer's disease LEQEMBI is the only ...

UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX® (bimekizumab-bkzx) is now available. These ...

Approval was based on results of the VIVID-1 study, which found that Omvoh demonstrated significant clinical remission and ...

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...

Biogen (BIIB) and Eisai's (ESALF) (ESAIY) announce that U.S. FDA agreed to review their subcutaneous form of Alzheimer's ...